HanchorBio, a company specializing in innovative immuno-oncology biologics, will be listed on Taiwan’s Emerging Stock Board on June 20. The lead underwriter has set a reference price of NT$50 per share, while the co-underwriter’s offering price is NT$56. The company’s first innovative drug, HCB101, entered a global Phase 1b/2a clinical trial in March 2025. A memorandum of understanding has been signed with an international pharmaceutical company for licensing in the Greater China region, with a final agreement expected in 2025. Meanwhile, its second fusion protein biologic candidate, HCB301, has received clearance from both the U.S. FDA and China’s NMPA to initiate Phase 1 clinical trials, with patient enrollment starting this quarter.
Built on its proprietary FBDB platform, HanchorBio focuses on developing fusion protein biologics designed to reactivate both innate and adaptive immune responses against cancer. The company targets the immune evasion pathway SIRPα/CD47 in tumor cells, with the potential to overcome the limitations of existing PD-1/PD-L1 immunotherapies. Two biologics are already in Phase 1 or 2 clinical stages, and one additional candidate is preparing for IND submission.
Chairman Wei-Ming Liu stated that HCB101 is a highly specific third-and-a-half generation SIRPα/CD47 fusion protein drug that effectively identifies and eliminates tumor cells without affecting red blood cells, offering improved safety compared to Gilead’s first-generation monoclonal antibody. In preclinical animal studies, HCB101 showed efficacy against 15 cancer types across 87 tumor models. Phase 1a clinical trials have confirmed the candidate’s strong safety profile. Early data from trials indicate a Partial Response (PR)—defined as more than a 30% reduction in total tumor diameter sustained over four weeks—in indications such as head and neck cancer and non-Hodgkin’s lymphoma, signaling promising potential for further clinical development. The global Phase 1b/2a trial began in March 2025 and is currently enrolling patients across leading medical centers in the U.S., Taiwan, and China to further assess efficacy and safety.
The second candidate, HCB301, has received Phase 1 clinical trial approval from both the FDA and NMPA, with patient recruitment initiated in Q2 2025. The company plans to pursue global licensing opportunities based on trial outcomes.
Regarding licensing, HCB101 is currently under a memorandum of understanding with an international pharmaceutical firm for rights in China, Hong Kong, and Macau, with a final deal expected in 2025, including upfront payments, milestone payments, and royalties. Several other global pharmaceutical companies are also conducting due diligence or in active licensing discussions, highlighting strong international interest and cooperation potential.
Resource: 漢康-KY 6/20登興櫃 創新藥HCB101中國授權今年將拍板
